Flourescence-based multiplex immunohistochemistry (mIHC) combined with multispectral imaging and digital image analysis (DIA) is a quantitative high-resolution method for determination of protein expression in tissue. We applied this method for five biomarkers (CDX2, SOX2, SOX9, E-cadherin, and beta-catenin) using tissue microarrays of a Norwegian unselected series of primary colorectal cancer. The data were compared with previously obtained chromogenic IHC data of the same tissue cores, visually assessed by the Allred method. We found comparable results between the methods, although confirmed that DIA offered improved resolution to differentiate cases with high and low protein expression. However, we experienced inherent challenges with di...
Abstract Immunohistochemical (IHC) assays performed on formalin-fixed paraffin-embedded (FFPE) tissu...
OBJECTIVES: The interaction between the immune system and tumor cells is an important feature for th...
Background The identification of high-risk stage II colon cancers is key to the selection of patient...
Flourescence-based multiplex immunohistochemistry (mIHC) combined with multispectral imaging and dig...
CDX1 and CDX2 are possibly predictive biomarkers in colorectal cancer. We combined digitally-guided ...
Multiplex immunofluorescence is a powerful tool for the simultaneous detection of tissue‐based bioma...
Assessment of the host immune response pattern is of increasing importance as highly prognostic and ...
The paradigm of molecular histopathology is shifting from a single-marker immunohistochemistry towar...
Background: Multiplex tissue analysis has revolutionized our understanding of the tumor microenviron...
Aim: Better stratification of patients with stage II and stage III colon cancer for risk of recurren...
Quantification of protein expression based on immunohistochemistry (IHC) is an important step in cli...
The purpose of this study was to determine whether staining intensity in conjunction with the percen...
The current prognosis and classification of CRC relies on staging systems that integrate histopathol...
The TSA Opal multiplex immunohistochemistry (mIHC) protocol (PerkinElmer) has been used to character...
Microsatellite instability (MSI) is present in 15-20% of primary colorectal cancers. MSI status is a...
Abstract Immunohistochemical (IHC) assays performed on formalin-fixed paraffin-embedded (FFPE) tissu...
OBJECTIVES: The interaction between the immune system and tumor cells is an important feature for th...
Background The identification of high-risk stage II colon cancers is key to the selection of patient...
Flourescence-based multiplex immunohistochemistry (mIHC) combined with multispectral imaging and dig...
CDX1 and CDX2 are possibly predictive biomarkers in colorectal cancer. We combined digitally-guided ...
Multiplex immunofluorescence is a powerful tool for the simultaneous detection of tissue‐based bioma...
Assessment of the host immune response pattern is of increasing importance as highly prognostic and ...
The paradigm of molecular histopathology is shifting from a single-marker immunohistochemistry towar...
Background: Multiplex tissue analysis has revolutionized our understanding of the tumor microenviron...
Aim: Better stratification of patients with stage II and stage III colon cancer for risk of recurren...
Quantification of protein expression based on immunohistochemistry (IHC) is an important step in cli...
The purpose of this study was to determine whether staining intensity in conjunction with the percen...
The current prognosis and classification of CRC relies on staging systems that integrate histopathol...
The TSA Opal multiplex immunohistochemistry (mIHC) protocol (PerkinElmer) has been used to character...
Microsatellite instability (MSI) is present in 15-20% of primary colorectal cancers. MSI status is a...
Abstract Immunohistochemical (IHC) assays performed on formalin-fixed paraffin-embedded (FFPE) tissu...
OBJECTIVES: The interaction between the immune system and tumor cells is an important feature for th...
Background The identification of high-risk stage II colon cancers is key to the selection of patient...